Article
Rheumatology
Mark D. Russell, Louise Ameyaw-Kyeremeh, Flora Dell'Accio, Heather Lapham, Natalie Head, Christopher Stovin, Vishit Patel, Benjamin D. Clarke, Deepak Nagra, Edward Alveyn, Maryam A. Adas, Katie Bechman, Maria A. de la Puente, Benjamin Ellis, Corrine Byrne, Rina Patel, Andrew Rutherford, Fleur Cantle, Sam Norton, Edward Roddy, Joanna Hudson, Andrew P. Cope, James B. Galloway
Summary: By optimizing the care for in-hospital gout flares, the strategy was successful in increasing the initiation of ULT and improving urate target attainment, while reducing re-hospitalizations. However, closer integration between primary and secondary care is still needed to improve urate target attainment for the majority of hospitalized gout patients.
Article
Rheumatology
Mark D. Russell, Edward Roddy, Andrew Rutherford, Benjamin Ellis, Sam Norton, Abdel Douiri, Martin C. Gulliford, Andrew P. Cope, James B. Galloway
Summary: The study found that treat-to-target urate-lowering therapy (ULT) reduces the risk of hospitalizations for gout in the long term, especially when serum urate targets are achieved. However, there is an increased risk of hospitalizations within the first 6 months after treatment initiation. Attaining a serum urate level <360 micromol/l within 12 months of initiation is associated with a reduced risk of hospitalizations.
Article
Rheumatology
Reem Alkilany, Douglas Einstadter, Maria Antonelli
Summary: This study retrospectively reviewed the UA level and the use of ULTs in patients with gout and ESRD on HD. The results showed a decrease in UA level associated with initiation of HD, indicating that discontinuation of ULTs may be appropriate for these patients.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2022)
Article
Immunology
Lei Pang, Xiaomei Xue, Yuwei He, Can Wang, Lin Han, Maichao Li, Han Qi, Changgui Li, Jie Lu
Summary: This study aimed to explore the relationship between the decrease in serum urate and the risk of gout flares during urate-lowering therapy (ULT) initiation. The results showed that the degree of decrease in serum urate is affected by baseline serum urate, and higher baseline serum urate and greater decrease in serum urate increase the risk of gout flares.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Article
Rheumatology
Xiaoli Li, Qin Shao, Jingfang Shen, Shaohui Ren, Lianju Li, Hua Lu, Shubo Chen
Summary: This observational study found that low-dose febuxostat and colchicine prophylaxis were equally effective in preventing gout flares, while high-dose febuxostat alone increased the risk of gout flares.
Article
Nanoscience & Nanotechnology
Jaeyong Jung, Ji-Hong Bong, Soo Jeong Lee, Moon-Ju Kim, Jeong Soo Sung, Misu Lee, Min-Jung Kang, Jungsik Song, Joachim Jose, Jae-Chul Pyun
Summary: A chromogenic assay for the diagnosis of gout and pseudogout using Fv antibodies with specific binding activities to MSU and CPPD crystals was proposed, eliminating the need for a polarized microscope and trained experts. Synthetic peptides labeled with biotin and streptavidin-horseradish peroxidase were used in a chromogenic assay configuration for crystal detection in the concentration range of 0-300 μg/mL in synovial fluid.
ACS APPLIED BIO MATERIALS
(2021)
Article
Dentistry, Oral Surgery & Medicine
Makoto Murahashi, Edward Hosea Ntege, Masaru Higa, Nobuyuki Maruyama, Toshihiro Kawano, Yusuke Shimizu, Hiroyuki Nakamura
Summary: The coexistence of calcium pyrophosphate dihydrate crystal deposition (CPP) and synovial chondromatosis (SC) in the temporomandibular joint (TMJ) is rare. This report presents a case of a 61-year-old man with coexisting CPP and SC in the TMJ. The patient experienced pain and trismus in the right TMJ and was initially diagnosed with SC based on radiographic assessments. However, histopathology revealed deposits of rhomboid and rod-shaped crystals positive for birefringence, confirming the coexistence of CPP. Surgical removal of loose bodies and chalk-like lesions was performed and after a follow-up of 1.5 years, no recurrence was observed.
Review
Chemistry, Medicinal
Adwoa Dansoa Tabi-Amponsah, Sarah Stewart, Graham Hosie, Lisa K. Stamp, William J. Taylor, Nicola Dalbeth
Summary: Urate-lowering therapies effectively reduce serum urate levels, monosodium urate crystal deposition, and the clinical symptoms of gout. The development of preliminary gout remission criteria in 2016 aims to achieve disease remission through specific measures such as maintaining low urate levels and absence of flares and tophi. This critical review provides an overview of the criteria, their properties, clinical studies on gout remission, and outlines a future research agenda.
Article
Rheumatology
Ployrung Laosuksri, Nathrudee Phrintrakul, Wanitcha Gumtorntip, Kittiya Na-Nan, Antika Wongthanee, Nuntana Kasitanon, Worawit Louthrenoo
Summary: The study found that non-loading low-dose colchicine was equally effective as loading low-dose colchicine in patients with acute crystal-associated arthritis, regardless of renal function or type of crystals.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Elizabeth Mitton-Fitzgerald, Claudia M. Gohr, Charlene M. Williams, Ann K. Rosenthal
Summary: Possible shared pathogenic pathways between CPPD and HHA are more related to bone and abnormal damage/repair mechanisms than direct damage to articular cartilage. While further research is needed to fully understand the pathogenesis of arthritis in HH and establish causal links with CPPD, this review provides plausible hypotheses explaining the overlap between these two forms of arthritis.
CURRENT RHEUMATOLOGY REPORTS
(2022)
Article
Rheumatology
Alwin Lian, Apoorva Shandilya, John Riordan
Summary: In this retrospective case series, the efficacy and safety of anakinra in treating calcium pyrophosphate deposition disease (CPPD) were assessed. The study found that anakinra had a rapid response and was well tolerated in CPPD patient cohort.
CLINICAL RHEUMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ching-Han Liu, Shih-Chung Huang, Chun-Hao Yin, Wei-Chun Huang, Jin-Shuen Chen, Yao-Shen Chen, Su-Ting Gan, Shiow-Jyu Tzou, Ching-Tsai Hsu, Hao-Ming Wu, Wen-Hwa Wang
Summary: Individuals of Asian descent have a higher risk of developing hyperuricemia and gout compared to Western populations. Urate-lowering therapy is effective in treating hyperuricemia and gout. However, the association between febuxostat, a type of urate-lowering therapy, and atrial fibrillation (AF) in Asian populations has not been properly investigated.
Article
Pharmacology & Pharmacy
Hongxing Li, Xinyue Zhang, Lili Gu, Qin Li, Yue Ju, Xuebin Zhou, Min Hu, Qin Li
Summary: This study comparatively investigated the therapeutic effects of wild and cultivated Phellinus igniarius on hyperuricaemia and gouty arthritis. The results showed that both types of Phellinus igniarius had similar activities in reducing uric acid levels and exhibited anti-inflammatory effects. They also reversed the pathological progression of kidney damage.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Rheumatology
Estrella Garcia-Gonzalez, Alessandra Gamberucci, Orso-Maria Lucherini, Alessandra Ali, Antonella Simpatico, Sauro Lorenzini, Pietro-Enea Lazzerini, Sergio Tripodi, Bruno Frediani, Enrico Selvi
Summary: The study found that during gout and pseudogout attacks, neutrophils in synovial fluid release NETs when encountering MSU and CPPD crystals, regardless of neutrophil density and crystal type. This release is accompanied by necroptosis through the activation of MLKL pathway.
Article
Medicine, General & Internal
Fu-Shun Yen, James Cheng-Chung Wei, Chia-Ling Chang, Chen-Chang Yang, Chih-Cheng Hsu, Chii-Min Hwu
Summary: Studies have shown that urate-lowering therapy (ULT) is not significantly associated with a lower risk of chronic kidney disease (CKD) development among gout patients. However, in specific patient subgroups such as those with diabetes mellitus and without hypertension, ULT may be significantly associated with a reduced risk of incident CKD.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)